Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
CNS Drugs
Published in: CNS Drugs 4/2008

01-04-2008 | Original Research Article

Pregnancy Outcome after In Utero Exposure to Valproate

Evidence of Dose Relationship in Teratogenic Effect

Authors: Orna Diav-Citrin, Svetlana Shechtman, Benjamin Bar-Oz, Dana Cantrell, Judy Arnon, Dr Asher Ornoy

Published in: CNS Drugs | Issue 4/2008

Login to get access

Abstract

Background: Valproate is a first-line antiepileptic agent and is also used in the treatment of bipolar disorder and migraine. It is a known human teratogen. The objective of the study was to evaluate the teratogenic risk of valproate.
Methods: All callers who contacted the Israeli Teratology Information Service (TIS) between 1994 and 2004 for information about gestational exposure to valproate were enrolled in the study. After the expected date of delivery, these women were followed up by telephone interview about their pregnancy outcome using a structured questionnaire. Data obtained from women who contacted the TIS about valproate exposure during pregnancy were then compared with data obtained from callers who were counselled for nonteratogenic exposures over the same timeframe. The main outcome measure was the rate of major congenital anomalies.
Results: The outcomes of 154 valproate-exposed pregnancies (96.1% at least in the first trimester) were compared with those of 1315 pregnancies of women in the TIS database who were counselled for nonteratogenic exposures. The rate of major anomalies (some multiple) in the valproate group exposed in the first trimester was higher compared with controls after exclusion of genetic or cytogenetic anomalies (8 of 120 [6.7%] vs 31 of 1236 [2.5%], p = 0.018, relative risk [RR] = 2.66, 95% CI 1.25, 5.65). There were no cases of neural tube defect in the valproate-exposed group. Five of the eight major anomalies in the valproate group were cardiovascular, two of eight were mentally retarded, two of five male infants with major anomalies had hypospadias and three of eight were suspected of having fetal valproate syndrome. A daily dose ≥1000 mg was associated with the highest teratogenic risk (7 of 32 [21.9%] vs 31 of 1236 [2.5%], RR = 8.72, 95% CI 4.16, 18.30). In the subgroup exposed to polytherapy there was a 4-fold increase in the rate of major anomalies compared with controls. All major anomalies were in the group treated for epilepsy.
Conclusion: When valproate treatment cannot be avoided in the first trimester of pregnancy, the lowest effective dose should be prescribed, preferably as monotherapy, to minimize its teratogenic risk.
Literature
1.
Schardein JL, ed. Chemically induced birth defects. New York: Marcel Dekker, Inc., 1993
2.
3.
Dalens B, Raynaud EJ, Gaulme J. Teratogenicity of valproic acid. J Pediatr 1980; 97: 332–3PubMed
4.
Gomez MR. Possible teratogenicity of valproic acid. J Pediatr 1981; 98: 508–9PubMed
5.
Stanley OH, Chambers TL. Sodium valproate and neural tube defects [letter]. Lancet 1982; 2: 1282CrossRef
6.
7.
Centers for Disease Control (CDC). Valproic acid and spina bifida: a preliminary report — France. MMWR Morb Mortal Wkly Rep 1982; 31: 565–6
8.
Robert E, Guibaud P. Maternal valproic acid and congenital neural tube defects [letter]. Lancet 1982; 2: 937PubMedCrossRef
9.
Bjerkedal T, Czeizel A, Goujard J, et al. Valproic acid and spina bifida [letter]. Lancet 1982; 2: 1096PubMedCrossRef
10.
Omtzigt JG, Los FJ, Grobbee DE, et al. The risk of spina bifida aperta after first-trimester exposure to valproate in a prenatal cohort. Neurology 1992; 42: 119–25PubMed
11.
DiLiberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984; 19: 473–81PubMedCrossRef
12.
Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29: 171–85PubMedCrossRef
13.
Bertollini R, Kallén B, Mastroiacovo P, et al. Anticonvulsant drugs in monotherapy: effect on the fetus. Eur J Epidemiol 1987; 3: 164–71PubMedCrossRef
14.
Rodriguez-Pinilla E, Arroyo I, Fondevilla J, et al. Prenatal exposure to valproic acid during pregnancy and limb deficiencies: a case-control study. Am J Med Genet 2000; 90: 376–81PubMedCrossRef
15.
Wide K, Winbladh B, Kallén B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 2004; 93: 174–6PubMedCrossRef
16.
Wyszynski DF, Nambisan M, Surve T, et al., on behalf of the Antiepileptic Drug Pregnancy Registry. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64: 961–5PubMedCrossRef
17.
Martinez-Frias ML, Rodriguez-Pinilla E, Salvador J. Valproate and spina bifida [letter]. Lancet 1989; 1: 611–2
18.
Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992; 42Suppl. 5: 75–82PubMed
19.
Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997; 38: 981–90PubMedCrossRef
20.
Kaaja E, Kaaja R, Hiilesmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003; 60: 575–9PubMedCrossRef
21.
Vajda FJ, O’Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of anti-epileptic drugs in pregnancy. J Clin Neurosci 2004; 11: 854–8PubMedCrossRef
22.
Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology 2005; 64: 1874–8PubMedCrossRef
23.
Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77: 193–8PubMedCrossRef
24.
Meador KJ, Baker GA, Finnell RH, et al., on behalf of the NEAD Study Group. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006; 67: 407–12PubMedCrossRef
25.
Koren G, Nava-Ocampo AA, Moretti ME, et al. Major malformations with valproic acid. Can Fam Physician 2006; 52: 441–7PubMed
26.
Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000; 37: 489–97PubMedCrossRef
27.
Dean JC, Hailey H, Moore SJ, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002; 39: 251–9PubMedCrossRef
28.
Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004; 75: 1575–83PubMedCrossRef
29.
Yerby MS. Pregnancy, teratogenesis, and epilepsy. Neurol Clin 1994; 12: 749–71PubMed
30.
Lindhout D, Omtzigt JG. Teratogenic effects of antiepileptic drugs: implications for the management of epilepsy in women of childbearing age. Epilepsia 1994; 35Suppl. 4: S19–28PubMedCrossRef
31.
Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988; 29: 459–67PubMedCrossRef
32.
Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies [editorial]. Teratology 1999; 59: 1–2PubMedCrossRef
33.
Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972; 2: 839–43PubMedCrossRef
34.
Bjerkedal T, Bahna SL. The course and outcome of pregnancy in women with epilepsy. Acta Obstet Gynecol Scand 1973; 52: 245–8PubMedCrossRef
35.
Shapiro S, Hartz SC, Siskind V, et al. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976; 1: 272–5PubMedCrossRef
36.
Fried S, Kozer E, Nulman I, et al. Malformation rates in children of women with untreated epilepsy. Drug Saf 2004; 27: 197–202PubMedCrossRef
37.
Laegreid L, Kyllerman M, Hedner T, et al. Benzodiazepine amplification of valproate teratogenic effects in children of mothers with absence epilepsy. Neuropediatrics 1993; 24: 88–92PubMedCrossRef
38.
39.
Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an International Database on Malformations and Drug Exposure (MADRE). Epilepsia 2000; 41: 1436–43PubMedCrossRef
Metadata
Title
Pregnancy Outcome after In Utero Exposure to Valproate
Evidence of Dose Relationship in Teratogenic Effect
Authors
Orna Diav-Citrin
Svetlana Shechtman
Benjamin Bar-Oz
Dana Cantrell
Judy Arnon
Dr Asher Ornoy
Publication date
01-04-2008
Publisher
Springer International Publishing
Published in
CNS Drugs / Issue 4/2008
Print ISSN: 1172-7047
Electronic ISSN: 1179-1934
DOI
https://doi.org/10.2165/00023210-200822040-00004

Other articles of this Issue 4/2008

CNS Drugs 4/2008 Go to the issue

Review Article

Current Management of Pain Associated with Multiple Sclerosis

Current Opinion

Use of Smoking Cessation Therapies in Individuals with Psychiatric Illness

Review Article

Assessing the Efficacy of Treatments for ADHD

Adis Drug Evaluation

Intramuscular Aripiprazole